Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer

Andrew J. Gunderson, Megan M. Kaneda, Takahiro Tsujikawa, Abraham V. Nguyen, Nesrine I. Affara, Brian Ruffell, Sara Gorjestani, Shannon M. Liudahl, Morgan Truit, Peter Olson, Grace Kim, Douglas Hanahan, Margaret A. Tempero, Brett Sheppard, Bryan Irving, Betty Y. Chang, Judith A. Varner, Lisa Coussens

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macrophage kinase, restores T cell– dependent antitumor immune responses, thereby inhibiting PDAC growth and improving responsiveness to standard-of-care chemotherapy. We report that PDAC tumor growth depends on cross-talk between B cells and FcRγ+ tumor–associated macrophages, resulting in TH2-type macrophage programming via BTK activation in a PI3Kγ-dependent manner. Treatment of PDAC-bearing mice with the BTK inhibitor PCI32765 (ibrutinib) or by PI3Kγ inhibition reprogrammed macrophages toward a TH1 phenotype that fostered CD8+ T-cell cytotoxicity, and suppressed PDAC growth, indicating that BTK signaling mediates PDAC immunosuppression. These data indicate that pharmacologic inhibition of BTK in PDAC can reactivate adaptive immune responses, presenting a new therapeutic modality for this devastating tumor type. SIGNIFICANCE: We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. Inhibition of BTK with the FDA-approved inhibitor ibrutinib restores T cell–dependent antitumor immune responses to inhibit PDAC growth and improves responsiveness to chemotherapy, presenting a new therapeutic modality for pancreas cancer.

Original languageEnglish (US)
Pages (from-to)270-285
Number of pages16
JournalCancer Discovery
Volume6
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Pancreatic Neoplasms
Tyrosine
Pancreas
Adenocarcinoma
Macrophages
B-Lymphocytes
Growth
T-Lymphocytes
Phosphatidylinositol 3-Kinases
Drug Therapy
Neoplasms
Adaptive Immunity
Therapeutics
Standard of Care
Agammaglobulinaemia tyrosine kinase
Immunosuppression
Phosphotransferases
Phenotype

ASJC Scopus subject areas

  • Oncology

Cite this

Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., ... Coussens, L. (2016). Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer. Cancer Discovery, 6(3), 270-285. https://doi.org/10.1158/2159-8290.CD-15-0827

Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer. / Gunderson, Andrew J.; Kaneda, Megan M.; Tsujikawa, Takahiro; Nguyen, Abraham V.; Affara, Nesrine I.; Ruffell, Brian; Gorjestani, Sara; Liudahl, Shannon M.; Truit, Morgan; Olson, Peter; Kim, Grace; Hanahan, Douglas; Tempero, Margaret A.; Sheppard, Brett; Irving, Bryan; Chang, Betty Y.; Varner, Judith A.; Coussens, Lisa.

In: Cancer Discovery, Vol. 6, No. 3, 01.03.2016, p. 270-285.

Research output: Contribution to journalArticle

Gunderson, AJ, Kaneda, MM, Tsujikawa, T, Nguyen, AV, Affara, NI, Ruffell, B, Gorjestani, S, Liudahl, SM, Truit, M, Olson, P, Kim, G, Hanahan, D, Tempero, MA, Sheppard, B, Irving, B, Chang, BY, Varner, JA & Coussens, L 2016, 'Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer', Cancer Discovery, vol. 6, no. 3, pp. 270-285. https://doi.org/10.1158/2159-8290.CD-15-0827
Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B et al. Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer. Cancer Discovery. 2016 Mar 1;6(3):270-285. https://doi.org/10.1158/2159-8290.CD-15-0827
Gunderson, Andrew J. ; Kaneda, Megan M. ; Tsujikawa, Takahiro ; Nguyen, Abraham V. ; Affara, Nesrine I. ; Ruffell, Brian ; Gorjestani, Sara ; Liudahl, Shannon M. ; Truit, Morgan ; Olson, Peter ; Kim, Grace ; Hanahan, Douglas ; Tempero, Margaret A. ; Sheppard, Brett ; Irving, Bryan ; Chang, Betty Y. ; Varner, Judith A. ; Coussens, Lisa. / Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer. In: Cancer Discovery. 2016 ; Vol. 6, No. 3. pp. 270-285.
@article{bf51f784752e48a9af0d872a979c2a74,
title = "Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer",
abstract = "Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macrophage kinase, restores T cell– dependent antitumor immune responses, thereby inhibiting PDAC growth and improving responsiveness to standard-of-care chemotherapy. We report that PDAC tumor growth depends on cross-talk between B cells and FcRγ+ tumor–associated macrophages, resulting in TH2-type macrophage programming via BTK activation in a PI3Kγ-dependent manner. Treatment of PDAC-bearing mice with the BTK inhibitor PCI32765 (ibrutinib) or by PI3Kγ inhibition reprogrammed macrophages toward a TH1 phenotype that fostered CD8+ T-cell cytotoxicity, and suppressed PDAC growth, indicating that BTK signaling mediates PDAC immunosuppression. These data indicate that pharmacologic inhibition of BTK in PDAC can reactivate adaptive immune responses, presenting a new therapeutic modality for this devastating tumor type. SIGNIFICANCE: We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. Inhibition of BTK with the FDA-approved inhibitor ibrutinib restores T cell–dependent antitumor immune responses to inhibit PDAC growth and improves responsiveness to chemotherapy, presenting a new therapeutic modality for pancreas cancer.",
author = "Gunderson, {Andrew J.} and Kaneda, {Megan M.} and Takahiro Tsujikawa and Nguyen, {Abraham V.} and Affara, {Nesrine I.} and Brian Ruffell and Sara Gorjestani and Liudahl, {Shannon M.} and Morgan Truit and Peter Olson and Grace Kim and Douglas Hanahan and Tempero, {Margaret A.} and Brett Sheppard and Bryan Irving and Chang, {Betty Y.} and Varner, {Judith A.} and Lisa Coussens",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/2159-8290.CD-15-0827",
language = "English (US)",
volume = "6",
pages = "270--285",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Bruton tyrosine kinase–Dependent immune cell cross-talk drives pancreas cancer

AU - Gunderson, Andrew J.

AU - Kaneda, Megan M.

AU - Tsujikawa, Takahiro

AU - Nguyen, Abraham V.

AU - Affara, Nesrine I.

AU - Ruffell, Brian

AU - Gorjestani, Sara

AU - Liudahl, Shannon M.

AU - Truit, Morgan

AU - Olson, Peter

AU - Kim, Grace

AU - Hanahan, Douglas

AU - Tempero, Margaret A.

AU - Sheppard, Brett

AU - Irving, Bryan

AU - Chang, Betty Y.

AU - Varner, Judith A.

AU - Coussens, Lisa

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macrophage kinase, restores T cell– dependent antitumor immune responses, thereby inhibiting PDAC growth and improving responsiveness to standard-of-care chemotherapy. We report that PDAC tumor growth depends on cross-talk between B cells and FcRγ+ tumor–associated macrophages, resulting in TH2-type macrophage programming via BTK activation in a PI3Kγ-dependent manner. Treatment of PDAC-bearing mice with the BTK inhibitor PCI32765 (ibrutinib) or by PI3Kγ inhibition reprogrammed macrophages toward a TH1 phenotype that fostered CD8+ T-cell cytotoxicity, and suppressed PDAC growth, indicating that BTK signaling mediates PDAC immunosuppression. These data indicate that pharmacologic inhibition of BTK in PDAC can reactivate adaptive immune responses, presenting a new therapeutic modality for this devastating tumor type. SIGNIFICANCE: We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. Inhibition of BTK with the FDA-approved inhibitor ibrutinib restores T cell–dependent antitumor immune responses to inhibit PDAC growth and improves responsiveness to chemotherapy, presenting a new therapeutic modality for pancreas cancer.

AB - Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all solid tumors, and thus new treatment strategies are urgently needed. Here, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macrophage kinase, restores T cell– dependent antitumor immune responses, thereby inhibiting PDAC growth and improving responsiveness to standard-of-care chemotherapy. We report that PDAC tumor growth depends on cross-talk between B cells and FcRγ+ tumor–associated macrophages, resulting in TH2-type macrophage programming via BTK activation in a PI3Kγ-dependent manner. Treatment of PDAC-bearing mice with the BTK inhibitor PCI32765 (ibrutinib) or by PI3Kγ inhibition reprogrammed macrophages toward a TH1 phenotype that fostered CD8+ T-cell cytotoxicity, and suppressed PDAC growth, indicating that BTK signaling mediates PDAC immunosuppression. These data indicate that pharmacologic inhibition of BTK in PDAC can reactivate adaptive immune responses, presenting a new therapeutic modality for this devastating tumor type. SIGNIFICANCE: We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. Inhibition of BTK with the FDA-approved inhibitor ibrutinib restores T cell–dependent antitumor immune responses to inhibit PDAC growth and improves responsiveness to chemotherapy, presenting a new therapeutic modality for pancreas cancer.

UR - http://www.scopus.com/inward/record.url?scp=84960124795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960124795&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-15-0827

DO - 10.1158/2159-8290.CD-15-0827

M3 - Article

C2 - 26715645

AN - SCOPUS:84960124795

VL - 6

SP - 270

EP - 285

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 3

ER -